39
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      New approaches to the study of sepsis

      review-article
      EMBO Molecular Medicine
      WILEY-VCH Verlag
      clinical trials, complement, interventions, mediators, sepsis

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Models of sepsis have been instructive in understanding the sequence of events in animals and, to an extent, in humans with sepsis. Events developing early in sepsis suggest that a hyperinflammatory state exists, accompanied by a buildup of oxidants in tissues reflective of a redox imbalance. Development of immunosuppression and degraded innate and adaptive immune responses are well-established complications of sepsis. In addition, there is robust activation of the complement system, which contributes to the harmful effects of sepsis. These events appear to be associated with development of multiorgan failure. The relevance of animal models of sepsis to human sepsis and the failure of human clinical trials are discussed, together with suggestions as to how clinical trial design might be improved.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          Role of C5a in inflammatory responses.

          The complement system not only represents an effective innate immune mechanism of host defense to eradicate microbial pathogens, but it is also widely involved in many forms of acute and chronic inflammatory diseases including sepsis, acute lung injury, ischemia-reperfusion injury, and asthma, to give just a few examples. The complement-activated product, C5a, displays powerful biological activities that lead to inflammatory sequelae. C5a is a strong chemoattractant and is involved in the recruitment of inflammatory cells such as neutrophils, eosinophils, monocytes, and T lymphocytes, in activation of phagocytic cells and release of granule-based enzymes and generation of oxidants, all of which may contribute to innate immune functions or tissue damage. Accumulating data suggest that C5a provides a vital bridge between innate and adaptive immune functions, extending the roles of C5a in inflammation. Herein, we review human and animal data describing the cellular and molecular mechanisms of C5a in the development of inflammatory disorders, sepsis, acute lung injury, ischemia-reperfusion injury, and asthma.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Management of Sepsis

            New England Journal of Medicine, 355(16), 1699-1713
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?

              Sepsis is a serious medical condition characterized by dysregulated systemic inflammatory responses followed by immunosuppression. To study the pathophysiology of sepsis, diverse animal models have been developed. Polymicrobial sepsis induced by cecal ligation and puncture (CLP) is the most frequently used model because it closely resembles the progression and characteristics of human sepsis. Here we summarize the role of several immune components in the pathogenesis of sepsis induced by CLP. However, several therapies proposed on the basis of promising results obtained by CLP could not be translated to the clinic. This demonstrates that experimental sepsis models do not completely mimic human sepsis. We propose several strategies to narrow the gap between experimental sepsis models and clinical sepsis, including targeting factors that contribute to the immunosuppressive phase of sepsis, and reproducing the heterogeneity of human patients. Copyright © 2011 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Journal
                EMBO Mol Med
                EMBO Mol Med
                emmm
                EMBO Molecular Medicine
                WILEY-VCH Verlag (Weinheim )
                1757-4676
                1757-4684
                December 2012
                04 December 2012
                : 4
                : 12
                : 1234-1243
                Affiliations
                Department of Pathology, University of Michigan Medical School Ann Arbor, MI, USA
                Author notes
                *Corresponding author: Tel: +1 734 647 2921; Fax: +1 734 764 4308; E-mail: pward@ 123456umich.edu
                Article
                10.1002/emmm.201201375
                3531600
                23208733
                1498c03f-a194-4833-b6cc-e6d3143fcf0e
                Copyright © 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO

                Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

                History
                : 13 August 2012
                : 13 September 2012
                : 05 October 2012
                Categories
                Review

                Molecular medicine
                clinical trials,complement,interventions,mediators,sepsis
                Molecular medicine
                clinical trials, complement, interventions, mediators, sepsis

                Comments

                Comment on this article